Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$0.46 - $0.78 $1,315 - $2,230
2,860 Added 0.83%
346,292 $186,000
Q1 2024

May 13, 2024

BUY
$0.48 - $0.85 $3,276 - $5,802
6,827 Added 2.03%
343,432 $240,000
Q4 2023

Feb 13, 2024

BUY
$0.38 - $0.82 $48,724 - $105,142
128,222 Added 61.53%
336,605 $276,000
Q3 2023

Nov 13, 2023

BUY
$0.65 - $1.04 $9,782 - $15,652
15,050 Added 7.78%
208,383 $137,000
Q2 2023

Aug 11, 2023

BUY
$0.98 - $1.11 $140 - $158
143 Added 0.07%
193,333 $201,000
Q1 2023

May 15, 2023

BUY
$0.98 - $1.06 $727 - $786
742 Added 0.39%
193,190 $195,000
Q4 2022

Feb 13, 2023

BUY
$0.96 - $28.0 $1,339 - $39,060
1,395 Added 0.73%
192,448 $192,000
Q3 2022

Nov 14, 2022

BUY
$1.06 - $27.75 $4,722 - $123,626
4,455 Added 2.39%
191,053 $204,000
Q2 2022

Aug 12, 2022

SELL
$1.07 - $1.55 $75,208 - $108,946
-70,288 Reduced 27.36%
186,598 $242,000
Q1 2022

May 13, 2022

BUY
$1.21 - $2.24 $1,712 - $3,169
1,415 Added 0.55%
256,886 $375,000
Q4 2021

Feb 11, 2022

BUY
$2.02 - $3.36 $311,253 - $517,728
154,086 Added 151.98%
255,471 $546,000
Q3 2021

Nov 12, 2021

SELL
$2.96 - $36.67 $228,076 - $2.83 Million
-77,053 Reduced 43.18%
101,385 $300,000
Q2 2021

Aug 13, 2021

BUY
$31.5 - $42.5 $2.86 Million - $3.86 Million
90,880 Added 103.79%
178,438 $6 Million
Q1 2021

May 12, 2021

BUY
$25.01 - $40.24 $239,345 - $385,096
9,570 Added 12.27%
87,558 $3 Million
Q4 2020

Feb 12, 2021

BUY
$28.66 - $46.79 $43,419 - $70,886
1,515 Added 1.98%
77,988 $2.84 Million
Q3 2020

Nov 13, 2020

BUY
$14.71 - $50.69 $838,808 - $2.89 Million
57,023 Added 293.18%
76,473 $3.71 Million
Q2 2020

Aug 13, 2020

BUY
$13.9 - $24.6 $270,355 - $478,470
19,450 New
19,450 $283,000

Others Institutions Holding FBRX

About Forte Biosciences, Inc.


  • Ticker FBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,340,300
  • Market Cap $115M
  • Description
  • Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
More about FBRX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.